Effectiveness of negative-pressure wound therapy in partial-thickness and full-thickness burns: a systematic review.

Acta Cir BrasSep 11, 2026 (epub)
Clinical ResearchGeneral SurgeryPlastic Surgery

Vanessa Cindy Oliveira Neres Lima de Souza, Ana Caroliny da Silva, Ruy de Souza Lino Junior et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effectiveness of negative-pressure wound therapy (NPWT) in healing partial- and full-thickness burns across eight studies involving 466 patients. The review found that NPWT significantly reduced re-epithelialization time, wound area, and bacterial load, with benefits noted in graft integration and healing quality.

Key findings

  • NPWT was superior in re-epithelialization time in three studies.
  • NPWT led to a greater reduction in wound area and bacterial load.
  • NPWT reduced dressing change frequency, enhancing care logistics.

Why it matters

Understanding the benefits of NPWT in burn treatment can help clinicians optimize healing outcomes and improve patient care logistics, particularly in managing complex burn injuries.

Source

PubMed · PMID 42752724

Published in Acta Cir Bras. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.